Literature DB >> 6241314

Role of serotonin in memory: facilitation by alaproclate and zimeldine.

H J Altman, D A Nordy, S O Ogren.   

Abstract

The effects of alaproclate and zimeldine on memory retrieval were examined in male Swiss-Webster mice using a one-trial inhibitory avoidance task. All drugs were administered IP prior to the retention test 24 h after training. Both drugs were found to facilitate memory retrieval significantly in a dose- and time-dependent fashion that could not be explained in terms of non-specific effects of the drug (illness, lack of motility, etc.) at the time of the test. The temporal effects of alaproclate and zimeldine on memory closely followed their course of concentration of the drug within the blood stream. The facilitation of retrieval induced by alaproclate and zimeldine was blocked by the putative serotonergic receptor agonist quipazine but not blocked by the antagonist cyproheptadine. Pretreatment with quipazine alone in a group of animals trained to a shock level which normally results in high levels of suppression was not sufficient to produce memory impairment, suggesting that quipazine was probably antagonizing the facilitative effects of alaproclate and zimeldine directly, rather than overriding the facilitation through an indirect action on retrieval in general. The present results lend further support to the suggestion that serotonin plays a significant role in memory.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6241314     DOI: 10.1007/bf00431456

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  23 in total

Review 1.  Some behavioral effects of serotonin depletion depend on method: a comparison of 5,7-dihydroxytryptamine, p-chlorophenylalanine, p-choloroamphetamine, and electrolytic raphe lesions.

Authors:  S A Lorens
Journal:  Ann N Y Acad Sci       Date:  1978-06-12       Impact factor: 5.691

2.  Mechanisms by which quipazine, a putative serotonin receptor agonist, alters brain 5-hydroxyindole metabolism.

Authors:  J H Jacoby; R A Howd; M S Levin; R J Wurtman
Journal:  Neuropharmacology       Date:  1976-09       Impact factor: 5.250

3.  (Z)-dimethylamino-1-(4-bromophenyl)-1-(3-pyridyl) propene (h 102/09), a new selective inhibitor of the neuronal 5-hydroxytryptamine uptake.

Authors:  S B Ross; S O Ogren; A L Renyi
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1976-08

4.  Peripheral serotonin antagonists: failure to antagonize serotonin in brain areas receiving a prominent serotonergic input.

Authors:  H J Haigler; G K Aghajanian
Journal:  J Neural Transm       Date:  1974       Impact factor: 3.575

5.  The effect of imipramine on central monoamine neurons.

Authors:  H Corrodi; K Fuxe
Journal:  J Pharm Pharmacol       Date:  1968-03       Impact factor: 3.765

6.  Demonstration of extraneuronal 5-hydroxytryptamine accumulation in brain following membrane-pump blockade by chlorimipramine.

Authors:  A Carlsson; J Jonason; M Lindqvist; K Fuxe
Journal:  Brain Res       Date:  1969-02       Impact factor: 3.252

7.  Tryptaminergic mechanisms in punished and nonpunished behavior.

Authors:  F G Graeff; R I Schoenfeld
Journal:  J Pharmacol Exp Ther       Date:  1970-06       Impact factor: 4.030

8.  Regulation of (3H)5-hydroxytryptamine release from rat brain slices.

Authors:  L O Farnebo; B Hamberger
Journal:  J Pharm Pharmacol       Date:  1974-08       Impact factor: 3.765

9.  Inhibition of the neuronal uptake of 5-hydroxytryptamine and noradrenaline in rat brain by (Z)- and (E)-3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridyl) allylamines and their secondary analogues.

Authors:  S B Ross; A L Renyi
Journal:  Neuropharmacology       Date:  1977-01       Impact factor: 5.250

10.  Antagonism of 5-hydroxytryptamine receptors by quipazine.

Authors:  M J Lansdown; H L Nash; P R Preston; D I Wallis; R G Williams
Journal:  Br J Pharmacol       Date:  1980-03       Impact factor: 8.739

View more
  9 in total

1.  Pretreatment with aldosterone or corticosterone blocks the memory-enhancing effects of nimodipine, captopril, CGP 37,849, and strychnine in mice.

Authors:  C Mondadori; C Gentsch; B Hengerer; T Ducret; J Borkowski; A Racine; R Lederer; A Haeusler
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  The effects of acute treatment with escitalopram on the different stages of contextual fear conditioning are reversed by atomoxetine.

Authors:  Liliana P Montezinho; Silke Miller; Niels Plath; Nanna Hovelsø Jensen; Jens-Jakob Karlsson; Louise Witten; Arne Mørk
Journal:  Psychopharmacology (Berl)       Date:  2010-07-30       Impact factor: 4.530

3.  Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database.

Authors:  Francois Chavant; Sylvie Favrelière; Claire Lafay-Chebassier; Caroline Plazanet; Marie-Christine Pérault-Pochat
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

Review 4.  Serotonin, memory, and the aging brain.

Authors:  W J McEntee; T H Crook
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  Effects of oxotremorine on inhibitory avoidance behaviour in two inbred strains of mice: interaction with 5-methoxy-NN-dimethyltriptamine.

Authors:  F Pavone; S Fagioli; C Castellano
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Chronic MDMA (ecstasy) use, cognition and mood.

Authors:  K McCardle; S Luebbers; J D Carter; R J Croft; C Stough
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

7.  Amitriptyline, clovoxamine and cognitive function: a placebo-controlled comparison in depressed outpatients.

Authors:  B Spring; A J Gelenberg; R Garvin; S Thompson
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 8.  [Relations between specific neurochemical systems and memory: problems posed by dementia of the Alzheimer type].

Authors:  I Lussier; E Stip
Journal:  J Psychiatry Neurosci       Date:  1995-01       Impact factor: 6.186

9.  A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer's disease mouse model.

Authors:  Jesus Campagna; Patricia Spilman; Barbara Jagodzinska; Dongsheng Bai; Asa Hatami; Chunni Zhu; Tina Bilousova; Michael Jun; Chris Jean Elias; Johnny Pham; Gregory Cole; Mary Jo LaDu; Michael E Jung; Dale E Bredesen; Varghese John
Journal:  Sci Rep       Date:  2018-12-04       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.